» Articles » PMID: 23696684

Skeletal Muscles of Ambulant Children with Duchenne Muscular Dystrophy: Validation of Multicenter Study of Evaluation with MR Imaging and MR Spectroscopy

Abstract

Purpose: To validate a multicenter protocol that examines lower extremity skeletal muscles of children with Duchenne muscular dystrophy (DMD) by using magnetic resonance (MR) imaging and MR spectroscopy in terms of reproducibility of these measurements within and across centers.

Materials And Methods: This HIPAA-compliant study was approved by the institutional review boards of all participating centers, and informed consent was obtained from each participant or a guardian. Standardized procedures with MR operator training and quality assurance assessments were implemented, and data were acquired at three centers by using different 3-T MR imaging instruments. Measures of maximal cross-sectional area (CSAmax), transverse relaxation time constant (T2), and lipid fraction were compared among centers in two-compartment coaxial phantoms and in two unaffected adult subjects who visited each center. Also, repeat MR measures were acquired twice on separate days in 30 boys with DMD (10 per center) and 10 unaffected boys. Coefficients of variation (CVs) were computed to examine the repeated-measure variabilities within and across centers.

Results: CSAmax, T2 from MR imaging and MR spectroscopy, and lipid fraction were consistent across centers in the phantom (CV, <3%) and in the adult subjects who traveled to each site (CV, 2%-7%). High day-to-day reproducibility in MR measures was observed in boys with DMD (CSAmax, CV = 3.7% [25th percentile, 1.3%; 75th percentile, 5.1%]; contractile area, CV = 4.2% [25th percentile, 0.8%; 75th percentile, 4.9%]; MR imaging T2, CV = 3.1% [25th percentile, 1.2%; 75th percentile, 4.7%]; MR spectroscopy T2, CV = 3.9% [25th percentile, 1.5%; 75th percentile, 5.1%]; and lipid fraction, CV = 4.7% [25th percentile, 1.0%; 75th percentile, 5.3%]).

Conclusion: The MR protocol implemented in this multicenter study achieved highly reproducible measures of lower extremity muscles across centers and from day to day in ambulatory boys with DMD.

Citing Articles

Serum protein and imaging biomarkers after intermittent steroid treatment in muscular dystrophy.

Willis A, Zelikovich A, Sufit R, Ajroud-Driss S, Vandenborne K, Demonbreun A Sci Rep. 2024; 14(1):28745.

PMID: 39567576 PMC: 11579281. DOI: 10.1038/s41598-024-79024-8.


Serum protein and imaging biomarkers after intermittent steroid treatment in muscular dystrophy.

Willis A, Zelikovich A, Sufit R, Ajroud-Driss S, Vandenborne K, Demonbreun A medRxiv. 2024; .

PMID: 38947030 PMC: 11213068. DOI: 10.1101/2024.06.14.24308858.


Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease.

McDonald C, Camino E, Escandon R, Finkel R, Fischer R, Flanigan K J Neuromuscul Dis. 2024; 11(2):499-523.

PMID: 38363616 PMC: 10977441. DOI: 10.3233/JND-230219.


Clinical importance of changes in magnetic resonance biomarkers for Duchenne muscular dystrophy.

Willcocks R, Barnard A, Daniels M, Forbes S, Triplett W, Brandsema J Ann Clin Transl Neurol. 2023; 11(1):67-78.

PMID: 37932907 PMC: 10791017. DOI: 10.1002/acn3.51933.


Compositional and Functional MRI of Skeletal Muscle: A Review.

Hooijmans M, Schlaffke L, Bolsterlee B, Schlaeger S, Marty B, Mazzoli V J Magn Reson Imaging. 2023; 60(3):860-877.

PMID: 37929681 PMC: 11070452. DOI: 10.1002/jmri.29091.


References
1.
Bushby K, Finkel R, Birnkrant D, Case L, Clemens P, Cripe L . Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2009; 9(1):77-93. DOI: 10.1016/S1474-4422(09)70271-6. View

2.
Wren T, Bluml S, Tseng-Ong L, Gilsanz V . Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study. AJR Am J Roentgenol. 2007; 190(1):W8-12. DOI: 10.2214/AJR.07.2732. View

3.
Frahm J, Bruhn H, Gyngell M, Merboldt K, Hanicke W, Sauter R . Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med. 1989; 9(1):79-93. DOI: 10.1002/mrm.1910090110. View

4.
Hoffman E, Brown Jr R, Kunkel L . Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987; 51(6):919-28. DOI: 10.1016/0092-8674(87)90579-4. View

5.
Deoni S, Williams S, Jezzard P, Suckling J, Murphy D, Jones D . Standardized structural magnetic resonance imaging in multicentre studies using quantitative T1 and T2 imaging at 1.5 T. Neuroimage. 2008; 40(2):662-671. DOI: 10.1016/j.neuroimage.2007.11.052. View